Nanomedicines from polymeric amphiphiles

Handbook of Materials for Nanomedicine

Volumn , Issue , 2010, Pages 495-513

  Uchegbu, Ijeoma F ^a   Lane, Majella ^a   Schatzlein, Andreas G ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855461781     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814267588     Document Type: Chapter

References (49)

1. X. Z. Qu et al., Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. Biomacromolecules, 7(12), 3452-3459 (2006).
2. A. A. Gabizon, Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new formof chemotherapy. Cancer Investig., 19(4), 424-436 (2001).
3. R. C. Mundargi et al., Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J. Contr. Rel., 125(3), 193-209 (2008).
4. G. Gregoriadis, Liposome Technology Volumes I, II and III, Boca Raton: CRC Press (2006).
5. I. F. Uchegbu, Pharmaceutical nanotechnology: Polymeric vesicles for drug and gene delivery. Expert Opin. Drug Deliv., 3, 629-640 (2006).
6. D. E. Discher and F. Ahmed, Polymersomes. Ann. Rev. Biomed., Engineer., 8, 323-341, (2006).
7. K. Kita-Tokarczyk et al., Block copolymer vesicles-Using concepts from polymer chemistry to mimic biomembranes. Polymer, 46(11), 3540-3563 (2005).
8. O. Uzun, et al., Recognition-induced polymersomes: Structure and mechanism of formation. Chem. A Eur. J., 11(23) 6916-6920 (2005).
9. B. Discher et al., Polymersomes: Tough vesicles made from diblock copolymers. Science, 284, 1143-1146 (1999).
10. D. E. Discher et al., Emerging applications of polymersomes in delivery: From molecular dynamics to shrinkage of tumors. Progr. Polymer Sci., 32(8-9), 838-857 (2007).
11. W. Wang et al., Self-assembly of cetyl linear polyethylenimine to give micelles, vesicles, and dense nanoparticles. Macromolecules, 37(24), 9114-9122 (2004).
12. X. Qu et al., Polymeric amphiphile branching leads to rare nano-disc shaped planar self assemblies. Langmuir, 24, 9997-10004 (2008).
13. M. D. Brown et al., Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents. Bioconjug. Chem., 11(6) 880-891 (2000).
14. M. D. Brown et al., In vitro and in vivo gene transfer with poly(amino acid) vesicles. J. Contr. Rel., 93, 193-211 (2003).
15. W. Wang, L. Tetley and I. F. Uchegbu, A new class of amphiphilic poly-L-lysine based polymers forms nanoparticles on probe sonication in aqueous media. Langmuir, 16(20), 7859-7866 (2000).
16. W. Wang, L. Tetley and I. F. Uchegbu, The level of hydrophobic substitution and the molecular weight of amphiphilic poly-Llysine- based polymers strongly affects their assembly into polymeric bilayer vesicles. J. Coll. Interf. Sci., 237(2), 200-207 (2001).
17. I. F. Uchegbu et al., Polymeric chitosan-based vesicles for drug delivery. J. Pharm. Pharmacol., 50(5) 453-8 (1998).
18. W. Wang et al., Controls on polymer molecular weight may be used to control the size of palmitoyl glycol chitosan polymeric vesicles. Langmuir, 17(3), 631-636 (2001).
19. J. H. Park et al., Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity. Biomaterials, 27(1), 119-126 (2006).
20. S. Kwon et al., Physicochemical characteristics of self-assembled nanoparticles based on glycol chitosan bearing 5 beta-cholanic acid. Langmuir, 19(24), 10188-10193 (2003).
21. W. P. Cheng et al., Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds. Biomacromolecules, 7(5), 1509-1520 (2006).
22. C. Tanford, The Hydrophobic Effect: Formation ofMicelles and Biological Membranes, John Wiley and Sons. New York (1980).
23. Y. Rharbi et al., Temperature dependence of fusion and fragmentation kinetics of Triton X-100 micelles. J. Am. Chem. Soc., 122(26), 6242-6251 (2000).
24. P. Alexandridis, J. F. Holzwarth and T. A. Hatton, Micellization of poly(ethylene oxide)-poly(propylene oxide)- poly(ethylene oxide) triblock copolymers in aqueous-solutions - thermodynamics of copolymer association. Macromolecules, 27(9), 2414-2425 (1994).
25. J. Israelachvili, Intermolecular & Surface Forces, 2 edn. Academic Press London (1991).
26. P. Kirkpatrick, Pressures in the pipeline. Nature Rev. Drug Discov., 2, 337 (2003).
27. G. Ismailos, C. Reppas, J. B. Dressman and P. Macheras, Unusual solubility behaviour of CsA in aqueous media. J. Pharm. Pharmacol., 43, 287-289 (1991).
28. G. Gregoriadis and J. Senior, Targeting of small unilamellar liposomes to the galactose receptor In vivo. Biochem. Soc. Trans., 12(2), 337-339 (1984).
29. M. N. Martinez and G. L. Amidon, A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J. Clin. Pharmacol., 42(6), 620-643 (2002).
30. H. van de Waterbeemd, The fundamental variables of the biopharmaceutics classification system (BCS): A commentary. Eur. J. Pharm. Sci., 7(1), 1-3 (1998).
31. A. L. Daugherty and R. J. Mrsny, Transcellular uptake mechanisms of the intestinal epithelial barrier - Part one. Pharm. Sci. Technol. Today, 2(4), 144-151 (1999).
32. N. N. Salama, N. D. Eddington and A. Fasano, Tight junction modulation and its relationship to drug delivery. Adv. Drug Del. Rev., 58(1), 15-28 (2006).
33. J. Hunter and B. H. Hirst, Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Del. Rev., 25(2-3), 129-157 (1997).
34. N. Blagden et al., Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Del. Rev., 59(7), 617-630 (2007).
35. D. Fleisher, R. Bong and B. H. Stewart, Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs. Adv. Drug Del. Rev., 19(2), 115-130 (1996).
36. R. N. Gursoy and S. Benita, Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother., 58(3), 173-182 (2004).
37. C. J. H. Porter, N. L. Trevaskis and W. N. Charman, Lipids and lipidbased formulations: optimizing the oral delivery of lipophilic drugs. Nature Rev. Discov., 6(3), 231-248 (2007).
38. H. J. Lee, Protein drug oral delivery: The recent progress. Arch. Pharm. Res., 25(5), 572-584 (2002).
39. J. F. Deeken and W. Loscher, The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin. Cancer Res., 13(6), 1663-1674 (2007).
40. W. M. Pardridge, The blood-brain barrier: Bottleneck in brain drug development. J. Am. Soc. Exp NeuroTherap., 2, 3-14 (2005).
41. D. J. Begley, The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol., 48(2), 136-146 (1996).
42. D. J. Begley, ABC transporters and the blood-brain barrier. Curr. Pharm. Des., 10(12), 1295-1312 (2004).
43. W. M. Pardridge, Drug targeting to the brain. Pharm. Res., 24(9), 1733-1744 (2007).
44. A. Beduneau et al., Brain targeting using novel lipid nanovectors. J. Contr. Rel., 126(1), 44-49 (2008).
45. S. Bihorel et al., Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res., 24(9), 1720-1728 (2007).
46. J. Kreuter et al., Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specificmechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res., 20(3), 409-416 (2003).
47. W. Lu et al., Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res., 66(24), 11878-11887 (2006).
48. M. D. Brown et al., Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents. Bioconjug. Chem., 11(6), 880-91 (2000).
49. M. D. Brown et al., In vitro and in vivo gene transfer with polyamino acid vesicles. J. Control. Rel., 93, 193-211 (2003).